Oncternal Therapeutics (ONCT) shares tumbled 33% in recent Monday premarket activity after it said in a regulatory filing that Nasdaq believes the company is a "public shell" and will adopt more "stringent" criteria for its listing after its Nov. 14 announcement of workforce reduction.
Actuate Therapeutics (ACTU) stock fell 21%, extending Friday's loss.
Akoustis Technologies (AKTS) shares slipped 20%, continuing the previous session's loss.
Macy's (M) stock fell more than 3% after it reported preliminary fiscal Q3 results and said it was delaying its quarterly earnings release due to an "issue" it identified regarding delivery expenditures in one of its accrual accounts.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。